Literature DB >> 3606914

Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure.

S Ward, N Boheimer, B C Weatherley, R J Simmonds, T A Dopson.   

Abstract

The plasma pharmacokinetic profiles of atracurium and its derivatives, laudanosine and monoquaternary alcohol, were studied in six patients with renal failure after a bolus dose of atracurium 0.3-0.4 mg kg-1. The pharmacokinetics of the derivatives only were studied in a group of four normal patients receiving atracurium 0.3 mg kg-1. Measurements of plasma and urine concentrations were performed by high pressure liquid chromatography. Pharmacokinetics of atracurium were not significantly different in the renal failure group when compared with those obtained in a previous study on six normal patients. Although 2-10% of the dose was recovered in the urine of normal patients as unchanged atracurium, and 3-4% as laudanosine, renal failure produced no significant differences in plasma pharmacokinetics, with mean plasma elimination half-lives of 20 min for atracurium, 234 min for laudanosine and 39 min for quaternary alcohol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606914     DOI: 10.1093/bja/59.6.697

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 3.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

5.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

6.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

Review 7.  Atracurium and laudanosine pharmacokinetics in acute renal failure.

Authors:  J M Hunter
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 8.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

9.  Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.

Authors:  V Nigrovic; M Banoub
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

10.  Consumption of Cisatracurium in different age groups, using a closed loop computer controlled system.

Authors:  Shehzaad Joomye; Donglai Yan; Haiyun Wang; Guoqiang Zhou; Guolin Wang
Journal:  BMC Anesthesiol       Date:  2014-04-21       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.